Trial Profile
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Dec 2022 Planned number of patients changed from 3000 to 1000.
- 21 Dec 2022 Planned End Date changed from 30 Apr 2022 to 8 Aug 2025.
- 21 Dec 2022 Planned primary completion date changed from 30 Apr 2022 to 8 Aug 2025.